NO.704

D001

MAY 1 9 2006

PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number. Application Number 10/719,102 Filing Date November 21, 2003 TRANSMITTAL First Named Inventor Elfatih Elzein **FORM** Art Unit 1624 **Examiner Name** BERCH, Mark L. (to be used for all correspondence after initial filing) **Attorney Docket Number** 01**-**0163-CIP2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(\$) Fee Transmittal Form Appeal Communication to Board of Appeals and Interferences Licensing-related Papers Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition  $|\mathbf{x}|$ Amendment/Reply Petition to Convert to a Proprietary Information X Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Request for Refund **Express Abandonment Request** CD. Number of CD(s)\_ Information Disclosure Statement Landscape Table on CD Remarks Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name CV Therapeutics, Inc Signature Printed name Ælin Hartrum Reg. No. 43,663 Date May 19, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postel Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on (571) 273-8300 the date shown below: Signature Date 05/19/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Approach of Complete this formation of the USPTO Complete the Chief Information of the USPTO Complete this formation of the USPTO Complete the USPTO Complete this formation of the USPTO Complete this complete this complete this complete the USPTO Complete this comp ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 1/28 \* RCVD AT 5/19/2006 12:55:31 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-2/7 \* DNIS:2738300 \* CSID:650 475 0359 \* DURATION (mm-ss):05-24

Susan Ahearn

Typed or printed name

## MAY 1 9 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/719,102

Applicant

Elzein et al.

Filed

November 21, 2003

Group Art Unit :

1624

Examiner

M. Berch

Confirmation No.

1946

Docket No.

01-163-CIP2

Title

A<sub>2B</sub> Adenosine Receptor Antagonists

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria VA, 22313-1450

## AMENDMENT UNDER 37 CFR § 1.116

In response to the Office action of March 31, 2006, please amend the above-identified application as follows.

Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.

Remarks begin on page 14 of this paper.